

- Burggraaff J, Knol DL, Uitdehaag BMJ. Regression-Based Norms for the Symbol Digit Modalities Test in the Dutch Population: Improving Detection of Cognitive Impairment in Multiple Sclerosis? *Eur Neurol.* 2017;77(5-6):246-252.

- Klauser AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, Uitdehaag BM, Barkhof F, Pouwels PJ, Geurts JJ. Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis. *Mult Scler.* 2017

- Meijer KA, Eijlers AJC, Douw L, Uitdehaag BMJ, Barkhof F, Geurts JJG, Schoonheim MM. Increased connectivity of hub networks and cognitive impairment in multiple sclerosis. *Neurology.* 2017 May 30;88(22):2107-2114.

- Balk LJ, Coric D, Nij Bijvank JA, Killestein J, Uitdehaag BM, Petzold A. Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis. *Mult Scler.* 2017

- Traboulsee AL, Cornelisse^a P, Sandberg-Wollheim M, Uitdehaag BM, Kappos L, Jongen PJ, Constantinescu CS, di Cantogno EV, Li DK. Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis. *Mult Scler J Exp Transl Clin.* 2016

- Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V. Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set. *Neurol Neuroimmunol Neuroinflamm.* 2017

- Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ. Five cases of malignant melanoma during Fingolimod treatment in Dutch patients with MS. *Neurology.* 2017 Aug 29;89(9):970-972.

- LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulas J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC). The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. *Mult Scler.* 2017

- Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. *Mult Scler.* 2017

- Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium. SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. *Mult Scler.* 2017